Monograph Details
|
|
Gastrointestinal Tract
> Hyperacidity, GERD, and ulcers
|
|
PEPCID |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
H2 blocker. |
| Generic Name |
|
Famotidine 20mg, 40mg; tabs. |
| Also |
• PEPCID INJECTION
• PEPCID INJECTION PREMIXED
• PEPCID SUSPENSION
|
| Indications |
|
Active duodenal ulcer. Maintenance of healed duodenal ulcer. Active benign gastric ulcer. Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome). Gastroesophageal reflux disease (GERD). Esophagitis due to GERD. |
| Children |
|
Individualize; adjust based on response. <1yr: not recommended. 1–16yrs: Peptic ulcer: Initially 0.5mg/kg per day at bedtime or in 2 divided doses; max 40mg/day. GERD: Initially 1mg/kg per day divided in 2 doses; max 40mg twice daily. |
| Adults |
|
Duodenal ulcer: 40mg once daily at bedtime or 20mg twice daily for 4–8 wks. Maintenance: 20mg once daily at bedtime. Benign gastric ulcer: 40mg once daily at bedtime for up to 8 wks. Hypersecretory conditions: Initially 20mg every 6 hrs; individualize. GERD symptoms: 20mg twice daily for up to 6 wks. Esophagitis: 20–40mg twice daily for up to 12 wks (see literature). |
| Precautions |
|
Moderate to severe renal insufficiency (CrCl <50mL/min): reduce dose or prolong dosing interval. Pregnancy (Cat.B). Nursing mothers: not recommended. |
| Interactions |
|
May give antacids concomitantly. |
| Adverse Reactions |
|
Headache, dizziness, constipation, diarrhea, somnolence, seizures, palpitations, depression, inj site reactions. |
| How Supplied |
Tabs—30, 90, 100, 1000
Susp—50mL
Inj single-dose vials (2mL)—10
Multidose vials (4mL)—1
Multidose vials (20mL)—1, 10
Premixed (50mL)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
